Vimarsana
Biggest News Aggregation in the World

Page 2 - Presented Today News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presented Today. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presented Today Today - Breaking & Trending Today

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action - Vimarsana News

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, Off-the-Shelf Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma - Vimarsana News

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, Off-the-Shelf Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

(0) Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021 BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24 th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021). The presentation at ASGCT 2021 will highlight data from six patients treated with the therapy. The results demonstrated a favorable safety profile with encouraging clinical...

SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast - Vimarsana News

SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast

TMCnet News SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast [December 11, 2020] SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast – Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment – – Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 -    – Data to be Presented Today at the San Anton...

Source: tmcnet.com